Jose Arribas, Ph.D. - Publications

Affiliations: 
2001 University of California, Los Angeles, Los Angeles, CA 
Area:
Curriculum and Instruction Education, Secondary Education, Mathematics Education

0/159 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
Low-probability matches
2016 Arsuaga M, Bujalance SG, Díaz-Menéndez M, Vázquez A, Arribas JR. Probable sexual transmission of Zika virus from a vasectomised man. The Lancet. Infectious Diseases. 16: 1107. PMID 27676342 DOI: 10.1016/S1473-3099(16)30320-6  0.04
2015 Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M, Madruga JV, Brunetta J, Shamblaw D, DeJesus E, Orkin C, Wohl DA, Brar I, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. The Lancet. Infectious Diseases. PMID 26538525 DOI: 10.1016/S1473-3099(15)00348-5  0.01
2014 Cahn P, Andrade-Villanueva J, Arribas JR, Gatell JM, Lama JR, Norton M, Patterson P, Sierra Madero J, Sued O, Figueroa MI, Rolon MJ. Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. The Lancet. Infectious Diseases. 14: 572-80. PMID 24783988 DOI: 10.1016/S1473-3099(14)70736-4  0.01
2013 Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES, van 't Wout AB, Lubomirov R, Colombo S, Martinez R, Rauch A, Günthard HF, Neuhaus J, Wentworth D, van Manen D, ... ... Arribas JR, et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 57: 112-21. PMID 23532479 DOI: 10.1093/cid/cit196  0.01
2011 Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. Aids Research and Human Retroviruses. 27: 29-34. PMID 20854196 DOI: 10.1089/aid.2010.0081  0.04
2010 Mora M, Rodriguez-Castellano E, Pano-Pardo JR, González-García J, Navarro C, Figueira JC, Arribas JR. Influenza A pandemic (H1N1) 2009 virus and HIV. Emerging Infectious Diseases. 16: 1175-6. PMID 20587202 DOI: 10.3201/eid1607.091339  0.04
2020 Rial-Crestelo D, de Miguel R, Montejano R, Dominguez-Dominguez L, Aranguren-Rivas P, Esteban-Cantos A, Bisbal O, Santacreu-Guerrero M, Garcia-Alvarez M, Alejos B, Hernando A, Bermejo-Plaza L, Cadiñanos J, Mayoral M, Castro JM, ... ... Arribas JR, et al. Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study. The Journal of Antimicrobial Chemotherapy. PMID 33200210 DOI: 10.1093/jac/dkaa479  0.01
2020 Rodríguez-Baño J, Pachón J, Carratalà J, Ryan P, Jarrín I, Yllescas M, Arribas JR, Berenguer J. Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19). Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. PMID 32860964 DOI: 10.1016/j.cmi.2020.08.010  0.01
2020 Latasa P, de Ory F, Arribas JR, Sánchez-Uriz MÁ, Sanchez-Arcilla I, Ordobás M, Negredo A, Trigo E, Delgado P, Marzola M, Lopaz MÁ, Sánchez-Seco MP, de la Calle-Prieto F, Ferrera P, Rodriguez E, et al. Absence of IgG antibodies among high-risk contacts of two confirmed cases of Crimean-Congo haemorrhagic fever in the autonomous region of Madrid (Spain). Journal of Infection and Public Health. PMID 32828715 DOI: 10.1016/j.jiph.2020.07.016  0.01
2020 Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, Jarrín I, Hernán MA. Antiretrovirals and risk of COVID-19 diagnosis and hospitalization in HIV-positive persons. Epidemiology (Cambridge, Mass.). PMID 32773469 DOI: 10.1097/EDE.0000000000001235  0.01
2020 Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, Yllescas M, Arribas JR. Characteristics and predictors of death among 4,035 consecutively hospitalized patients with COVID-19 in Spain. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. PMID 32758659 DOI: 10.1016/j.cmi.2020.07.024  0.01
2020 Refoyo E, Troya J, Trigo E, Guzmán-Martinez G, Valbuena-López S, Caro-Codón J, Rosillo S, Moreno-Yanguela M, Tamargo J, Arribas JR, Acquatella H, Lopez-Sendon J. Comparison of Noninvasive Cardiac Test Strategies for Newly Diagnosed Chagas Disease in a Non-Endemic Zone. The American Journal of Tropical Medicine and Hygiene. PMID 32700660 DOI: 10.4269/ajtmh.20-0389  0.01
2020 Condes E, Arribas JR. Impact of COVID-19 on Madrid hospital system. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 32680795 DOI: 10.1016/j.eimc.2020.06.005  0.01
2020 Del Amo J, Polo R, Moreno S, Díaz A, Martínez E, Arribas JR, Jarrín I, Hernán MA. Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy: A Cohort Study. Annals of Internal Medicine. PMID 32589451 DOI: 10.7326/M20-3689  0.01
2020 Borobia AM, Carcas AJ, Arnalich F, Álvarez-Sala R, Monserrat-Villatoro J, Quintana M, Figueira JC, Torres Santos-Olmo RM, García-Rodríguez J, Martín-Vega A, Buño A, Ramírez E, Martínez-Alés G, García-Arenzana N, Núñez MC, ... ... Arribas JR, et al. A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe. Journal of Clinical Medicine. 9. PMID 32512688 DOI: 10.3390/jcm9061733  0.01
2020 Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo F, Thompson MA, Podzamczer D, Hagins D, Flamm JA, Brinson C, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. The Lancet. Hiv. 7: e389-e400. PMID 32504574 DOI: 10.1016/S2352-3018(20)30099-0  0.01
2020 García IG, Rodriguez-Rubio M, Mariblanca AR, de Soto LM, García LD, Villatoro JM, Parada JQ, Meseguer ES, Rosales MJ, González J, Arribas JR, Carcas AJ, de la Oliva P, Borobia AM. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. Trials. 21: 466. PMID 32493475 DOI: 10.1186/s13063-020-04436-6  0.01
2020 De Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, Montejano R, Esteban-Cantos A, Aranguren-Rivas P, Stella-Ascariz N, Bisbal O, Bermejo-Plaza L, Garcia-Alvarez M, Alejos B, Hernando A, Santacreu-Guerrero M, Cadiñanos J, Mayoral M, ... ... Arribas JR, et al. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). Ebiomedicine. 55: 102779. PMID 32408111 DOI: 10.1016/j.ebiom.2020.102779  0.01
2020 Gaborit BJ, Bergmann JF, Mussini C, Arribas JR, Behrens G, Walmsley S, Pozniak A, Raffi F. Plea for multitargeted interventions for severe COVID-19. The Lancet. Infectious Diseases. PMID 32325035 DOI: 10.1016/S1473-3099(20)30312-1  0.01
2020 Ramos-Ramos JC, Lázaro-Perona F, Arribas JR, García-Rodríguez J, Mingorance J, Ruiz-Carrascoso G, Borobia AM, Paño-Pardo JR, Herruzo R, Arnalich F. Proof-of-concept trial of the combination of lactitol with and for the eradication of intestinal OXA-48-producing . Gut Pathogens. 12: 15. PMID 32280375 DOI: 10.1186/s13099-020-00354-9  0.01
2020 Chalouni M, Rodriguez-Centeno J, Samri A, Blanco J, Stella-Ascariz N, Wallet C, Knobel H, Zucman D, Alejos Ferreras B, Autran B, Thiebaut R, Raffi F, Arribas JR. Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals. Plos One. 15: e0230772. PMID 32267847 DOI: 10.1371/journal.pone.0230772  0.01
2019 Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Tenorio AR, et al. Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 31834000 DOI: 10.1097/QAI.0000000000002275  0.01
2019 Arribas JM, Soriano L, Rivera-Caravaca JM, Lorenzo M, Muñoz C, Taboada R, Jiménez A, Martínez J, García-Puente J, Gutiérrez F, Manzano S, Cánovas S. Incidence and causes of pacemaker implantation during postoperative period of aortic valve replacement with rapid deployment prosthesis. Pacing and Clinical Electrophysiology : Pace. PMID 31677175 DOI: 10.1111/pace.13824  0.01
2019 Pozniak AL, Arribas JR. Dolutegravir-rilpivirine for virological suppression. The Lancet. Hiv. PMID 31307947 DOI: 10.1016/S2352-3018(19)30188-2  0.01
2019 Stellbrink HJ, Arribas JR, Stephens JL, Albrecht H, Sax PE, Maggiolo F, Creticos C, Martorell CT, Wei X, Acosta R, Collins SE, Brainard D, Martin H. Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet. Hiv. PMID 31068272 DOI: 10.1016/S2352-3018(19)30080-3  0.01
2019 Gupta SK, Post FA, Arribas JR, Jr JJE, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ, Esser S, Pozniak AL, Podzamczer D, Waters L, Orkin C, Rockstroh JK, Mudrikova T, et al. Renal safety of tenofovir alafenamide vs tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials. Aids (London, England). PMID 30932951 DOI: 10.1097/QAD.0000000000002223  0.01
2019 Kuhn JH, Adachi T, Adhikari NKJ, Arribas JR, Bah IE, Bausch DG, Bhadelia N, Borchert M, Brantsæter AB, Brett-Major DM, Burgess TH, Chertow DS, Chute CG, Cieslak TJ, Colebunders R, et al. New filovirus disease classification and nomenclature. Nature Reviews. Microbiology. PMID 30926957 DOI: 10.1038/s41579-019-0187-4  0.01
2019 Bernardino JI, Mocroft A, Wallet C, de Wit S, Katlama C, Reiss P, Mallon PW, Richert L, Molina JM, Knobel H, Morlat P, Babiker A, Pozniac A, Raffi F, Arribas JR, et al. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial. Plos One. 14: e0209911. PMID 30689664 DOI: 10.1371/journal.pone.0209911  0.01
2018 Tello-Montoliu A, Albaladejo P, Hernández-Romero D, Taboada R, Albacete CL, Arribas JM, Jara R, Veliz A, López-García C, Cánovas S, Valdés M, Rivera-Caravaca JM, Marín F. Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test. Circulation. Cardiovascular Interventions. 11: e007264. PMID 30525983 DOI: 10.1161/CIRCINTERVENTIONS.118.007264  0.01
2018 Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet (London, England). PMID 30420123 DOI: 10.1016/S0140-6736(18)32462-0  0.01
2018 Thompson JA, Kityo C, Dunn D, Hoppe A, Ndashimye E, Hakim J, Kambugu A, van Oosterhout JJ, Arribas J, Mugyenyi P, Walker AS, Paton NI. Evolution of protease inhibitor resistance in HIV-1-infected patients failing protease inhibitor monotherapy as second-line therapy in low-income countries: an observational analysis within the EARNEST randomised trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 30060027 DOI: 10.1093/cid/ciy589  0.01
2018 Stella-Ascariz N, Montejano R, Rodriguez-Centeno J, Alejos B, Schwimmer C, Bernardino JI, Rodes B, Allavena C, Hoffmann C, Gisslén M, de Miguel R, Esteban-Cantos A, Wallet C, Raffi F, Arribas JR, et al. Blood Telomere Length Changes after Ritonavir-boosted Darunavir Combined with Raltegravir or Tenofovir-Emtricitabine in Antiretroviral-Naive Adults Infected with HIV-1. The Journal of Infectious Diseases. PMID 29982509 DOI: 10.1093/infdis/jiy399  0.01
2018 Luczkowiak J, Lasala F, Mora-Rillo M, Arribas JR, Delgado R. Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. The Journal of Infectious Diseases. PMID 29939289 DOI: 10.1093/infdis/jiy302  0.01
2018 Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Valencia E, Martín-Carbonero L, Moreno V, González-Garcia J, Rodriguez-Centeno J, Rodes B, Esteban Cantos A, Alejos B, de Miguel R, ... ... Arribas JR, et al. Impact of Nucleos(t)ide Reverse Transcriptase Inhibitors on Blood Telomere Length Changes in a Prospective Cohort of Aviremic HIV-1 infected Adults. The Journal of Infectious Diseases. PMID 29912427 DOI: 10.1093/infdis/jiy364  0.01
2018 Pérez-Molina JA, Martínez E, Blasco AJ, Arribas JR, Domingo P, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Mariño A, Miró JM, Moreno S, Negredo E, Pulido F, et al. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 29884455 DOI: 10.1016/j.eimc.2018.04.010  0.01
2018 Young C, Laufer G, Kocher A, Solinas M, Alamanni F, Polvani G, Podesser BK, Aramendi JI, Arribas J, Bouchot O, Livi U, Massetti M, Terp K, Giot C, Glauber M. One-year outcomes after rapid-deployment aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery. 155: 575-585. PMID 29415382 DOI: 10.1016/j.jtcvs.2017.09.133  0.01
2018 Pericàs JM, Moreno A, Almela M, García-de-la-Mària C, Marco F, Muñoz P, Peña C, de Alarcón A, Río AD, Eworo A, Cruceta A, Paré JC, Mestres CA, Miró JM, ... ... Arribas JR, et al. Efficacy and Safety of Fosfomycin Plus Imipenem vs. Vancomycin for Complicated Bacteremia and Endocarditis Due to Methicillin-Resistant Staphylococcus aureus: A Randomized Clinical Trial. Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. PMID 29408610 DOI: 10.1016/j.cmi.2018.01.010  0.01
2018 de Miguel Buckley R, Montejano R, Stella-Ascariz N, Arribas JR. New Strategies of ARV: the Road to Simplification. Current Hiv/Aids Reports. PMID 29353398 DOI: 10.1007/s11904-018-0371-6  0.01
2017 Stella-Ascariz N, Arribas JR, Paredes R, Li JZ. The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure. The Journal of Infectious Diseases. 216: S847-S850. PMID 29207001 DOI: 10.1093/infdis/jix430  0.01
2017 de Miguel R, Montejano R, Stella-Ascariz N, Arribas JR. A safety evaluation of raltegravir for the treatment of HIV. Expert Opinion On Drug Safety. 1-7. PMID 29199485 DOI: 10.1080/14740338.2018.1411903  0.01
2017 García-Bujalance S, Gutiérrez-Arroyo A, De la Calle F, Díaz-Menéndez M, Arribas JR, García-Rodríguez J, Arsuaga M. Persistence and infectivity of Zika virus in semen after returning from endemic areas: Report of 5 cases. Journal of Clinical Virology : the Official Publication of the Pan American Society For Clinical Virology. 96: 110-115. PMID 29053990 DOI: 10.1016/j.jcv.2017.10.006  0.01
2017 Pulido F, Ribera E, Lagarde M, Pérez-Valero I, Palacios R, Iribarren JA, Payeras A, Domingo P, Sanz J, Cervero M, Curran A, Rodríguez-Gómez FJ, Téllez MJ, Ryan P, Barrufet P, ... ... Arribas JR, et al. Dual therapy with darunavir and ritonavir plus lamivudine versus triple therapy with darunavir and ritonavir plus tenofovir disoproxil fumarate and emtricitabine or abacavir and lamivudine for maintenance of HIV-1 viral suppression: randomised, open label, non-inferiority DUAL-GESIDA 8014-RIS-EST45 trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29020293 DOI: 10.1093/cid/cix734  0.01
2017 Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. The Lancet. Hiv. PMID 28993180 DOI: 10.1016/S2352-3018(17)30179-0  0.01
2017 Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, et al. Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 28991888 DOI: 10.1097/QAI.0000000000001562  0.01
2017 Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M, Astray-Mochales J, Sánchez-Seco MP, Bermejo Lopez E, Menárguez J, Fernández-Cruz A, Sánchez-Artola B, Keough-Delgado E, Ramírez de Arellano E, Lasala F, Milla J, Fraile JL, ... ... Arribas JR, et al. Autochthonous Crimean-Congo Hemorrhagic Fever in Spain. The New England Journal of Medicine. 377: 154-161. PMID 28700843 DOI: 10.1056/NEJMoa1615162  0.01
2017 de la Calle-Prieto F, Martín-Quirós A, Trigo E, Mora-Rillo M, Arsuaga M, Díaz-Menéndez M, Arribas JR. Therapeutic management of Crimean-Congo haemorrhagic fever. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 28669587 DOI: 10.1016/j.eimc.2017.04.007  0.01
2017 Mora-Rillo M, Díaz-Menéndez M, Crespillo-Andujar C, Arribas JR. Autochthonous Crimean-Congo haemorrhagic fever in Spain: So much to learn. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 28651786 DOI: 10.1016/j.eimc.2017.05.004  0.01
2017 Arribas JR, DeJesus E, van Lunzen J, Zurawski C, Doroana M, Towner W, Lazzarin A, Nelson M, McColl D, Andreatta K, Swamy R, Szwarcberg J, Nguyen T. Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PI. Hiv Clinical Trials. 1-8. PMID 28555519 DOI: 10.1080/15284336.2017.1330440  0.01
2017 Halperin SA, Arribas JR, Rupp R, Andrews CP, Chu L, Das R, Simon JK, Onorato MT, Liu K, Martin J, Helmond FA. Six-Month Safety Data of Recombinant Vesicular Stomatitis Virus-Zaire Ebola Virus Envelope Glycoprotein Vaccine in a Phase 3 Double-Blind, Placebo-Controlled Randomized Study in Healthy Adults. The Journal of Infectious Diseases. PMID 28549145 DOI: 10.1093/infdis/jix189  0.01
2017 Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Asensi V, Crespo M, Domingo P, Iribarren JA, Lázaro P, López-Aldeguer J, Lozano F, Martínez E, Moreno S, Palacios R, Pineda JA, et al. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 28532596 DOI: 10.1016/j.eimc.2017.04.002  0.01
2017 Montejano R, Stella-Ascariz N, Monge S, Bernardino JI, Pérez-Valero I, Montes M, Valencia E, Martín-Carbonero L, Moreno V, González-García J, Arnalich F, Mingorance J, Berniches LP, Perona R, Arribas JR. Impact of antiretroviral treatment containing tenofovir difumarate on the telomere length of aviremic HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 28418989 DOI: 10.1097/QAI.0000000000001391  0.01
2017 Arribas JR, Thompson M, Sax PE, Haas B, McDonald C, Wohl DA, DeJesus E, Clarke AE, Guo S, Wang H, Callebaut C, Plummer A, Cheng A, Das M, McCallister S. A Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), Each Coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 28282300 DOI: 10.1097/QAI.0000000000001350  0.01
2016 Díaz-Menéndez M, de la Calle-Prieto F, Montero D, Antolín E, Vazquez A, Arsuaga M, Trigo E, García-Bujalance S, de la Calle M, Sánchez Seco P, de Ory F, Arribas JR. Initial experience with imported Zika virus infection in Spain. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 27743683 DOI: 10.1016/j.eimc.2016.08.003  0.01
2016 Paño-Pardo JR, López Quintana B, Lázaro Perona F, Ruiz Carrascoso G, Romero-Gómez MP, Loeches Yagüe B, Díaz-Pollán B, Martínez-Virto A, Mingorance J, García Rodríguez J, Arribas JR, Gómez-Gil R. Community-Onset Bloodstream and Other Infections, Caused by Carbapenemase-Producing Enterobacteriaceae: Epidemiological, Microbiological, and Clinical Features. Open Forum Infectious Diseases. 3: ofw136. PMID 27703997 DOI: 10.1093/ofid/ofw136  0.01
2016 Stella-Ascariz N, Montejano R, Pintado-Berninches L, Monge S, Bernardino JI, Pérez-Valero I, Montes ML, Mingorance J, Perona R, Arribas JR. Differential effects of Tenofovir, Abacavir, Emtricitabine and Darunavir on telomerase activity in vitro. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 27552152 DOI: 10.1097/QAI.0000000000001154  0.01
2016 Rivero A, Pérez-Molina JA, Blasco AJ, Arribas JR, Crespo M, Domingo P, Estrada V, Iribarren JA, Knobel H, Lázaro P, López-Aldeguer J, Lozano F, Moreno S, Palacios R, Pineda JA, et al. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 27459919 DOI: 10.1016/j.eimc.2016.06.013  0.01
2016 Arribas JR, Luczkowiak J, Delgado R. Convalescent Plasma for Ebola Virus Disease. The New England Journal of Medicine. 374: 2498-500. PMID 27332914 DOI: 10.1056/NEJMc1602284#SA1  0.01
2016 Saumoy M, Llibre JM, Terrón A, Knobel H, Arribas J, Domingo P, Arroyo-Manzano D, Rivero A, Moreno S, Podzamczer D. MARAVIROC ONCE-DAILY: EXPERIENCE IN ROUTINE CLINICAL PRACTICE. Aids Research and Human Retroviruses. PMID 27250802 DOI: 10.1089/AID.2015.0386  0.01
2016 Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, et al. Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 27056581 DOI: 10.1016/j.eimc.2016.02.025  0.01
2016 Stella-Ascariz N, Montejano R, Martin-Vicente M, Mingorance J, Pérez-Valero I, Bernardino JI, Arribas JR. Long-Term Control of Human Immunodeficiency Virus-1 Replication Despite Extensive Resistance to Current Antiretroviral Regimens: Clonal Analysis of Resistance Mutations in Proviral Deoxyribonucleic Acid. Open Forum Infectious Diseases. 3: ofw041. PMID 27006965 DOI: 10.1093/ofid/ofw041  0.01
2016 Iribarren JA, Rubio R, Aguirrebengoa K, Arribas JR, Baraia-Etxaburu J, Gutiérrez F, Lopez Bernaldo de Quirós JC, Losa JE, Miró JM, Moreno S, Pérez Molina J, Podzamczer D, Pulido F, Riera M, Rivero A, et al. Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 26976381 DOI: 10.1016/j.eimc.2016.02.004  0.01
2016 Uyeki TM, Mehta AK, Davey RT, Liddell AM, Wolf T, Vetter P, Schmiedel S, Grünewald T, Jacobs M, Arribas JR, Evans L, Hewlett AL, Brantsaeter AB, Ippolito G, Rapp C, et al. Clinical Management of Ebola Virus Disease in the United States and Europe. The New England Journal of Medicine. 374: 636-46. PMID 26886522 DOI: 10.1056/NEJMoa1504874  0.01
2016 Wohl D, Oka S, Clumeck N, Clarke A, Brinson C, Stephens J, Tashima K, Arribas JR, Rashbaum B, Cheret A, Brunetta J, Mussini C, Tebas P, Sax PE, Cheng A, et al. A Randomized, Double-Blind comparison of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil fumarate (TDF), each coformulated with Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for initial HIV-1 Treatment: Week 96 results. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 26829661 DOI: 10.1097/QAI.0000000000000940  0.01
2016 de la Calle-Prieto F, Arsuaga-Vicente M, Mora-Rillo M, Arnalich-Fernandez F, Arribas JR. [Ebola virus disease: Update]. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 26774254 DOI: 10.1016/j.eimc.2015.11.013  0.01
2016 Sendagorta E, Bernardino JI, Álvarez-Gallego M, Feíto M, Feltes R, Beato MJ, Pérez-Molina JA, Yllescas M, Díaz-Almirón M, Arribas JR, González-García J, Herranz P. Topical cidofovir to treat high-grade anal intraepithelial neoplasia in HIV-infected patients: a pilot clinical trial. Aids (London, England). 30: 75-82. PMID 26731755 DOI: 10.1097/QAD.0000000000000886  0.01
2016 van Lunzen J, Antinori A, Cohen CJ, Arribas JR, Wohl DA, Rieger A, Rachlis A, Bloch M, Segal-Maurer S, Garner W, Porter D, Bosse M, Piontkowsky D, Chuck SK, De-Oertel S. Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study. Aids (London, England). 30: 251-9. PMID 26684822 DOI: 10.1097/QAD.0000000000000911  0.01
2015 Luczkowiak J, Arribas JR, Gómez S, VJiménez-Yuste V, de la Calle F, Viejo A, Delgado R. Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. Virus Research. PMID 26739425 DOI: 10.1016/j.virusres.2015.12.019  0.01
2015 Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, Phase 3 study. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 26627107 DOI: 10.1097/QAI.0000000000000908  0.01
2015 Hernández-Romero D, Lahoz Á, Roldan V, Jover E, Romero-Aniorte AI, Martinez CM, Jara-Rubio R, Arribas JM, Garcia-Alberola A, Cánovas S, Valdés M, Marín F. Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups On Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology. PMID 26566941 DOI: 10.1093/europace/euv354  0.01
2015 Bernardino JI, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, Reiss P, Katlama C, De Wit S, Richert L, Babiker A, Buño A, Castagna A, Girard PM, Chene G, ... ... Arribas JR, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. The Lancet. Hiv. 2: e464-73. PMID 26520926 DOI: 10.1016/S2352-3018(15)00181-2  0.01
2015 Pérez-Valero I, Arribas JR. Second-line antiretroviral therapy and the human factor. The Lancet. Hiv. 2: e34-5. PMID 26424456 DOI: 10.1016/S2352-3018(15)00003-X  0.01
2015 Antinori A, Clarke A, Svedhem-Johansson V, Arribas JR, Arenas-Pinto A, Fehr J, Gerstoft J, Horban A, Clotet B, Ripamonti D, Girard PM, Hill AM, Moecklinghoff C. Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analogues. Aids (London, England). 29: 1811-20. PMID 26372387 DOI: 10.1097/QAD.0000000000000778  0.01
2015 Berenguer J, Rivero A, Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, Lázaro P, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, et al. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 26321131 DOI: 10.1016/j.eimc.2015.07.012  0.01
2015 Gathe J, Arribas JR, Van Lunzen J, Garner W, Speck RM, Bender R, Shreay S, Nguyen T. Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF. The Patient. 8: 445-54. PMID 26286337 DOI: 10.1007/s40271-015-0137-9  0.01
2015 Sepriano A, Roman-Blas JA, Little RD, Pimentel-Santos F, Arribas JM, Largo R, Branco JC, Herrero-Beaumont G. DXA in the assessment of subchondral bone mineral density in knee osteoarthritis--A semi-standardized protocol after systematic review. Seminars in Arthritis and Rheumatism. 45: 275-83. PMID 26188773 DOI: 10.1016/j.semarthrit.2015.06.012  0.01
2015 Pérez-Andreu J, Ray VG, Arribas JM, Sánchez SJ. Ellis-van Creveld syndrome in adulthood: extending the clinical spectrum. Singapore Medical Journal. 56: e110-1. PMID 26106249 DOI: 10.11622/smedj.2015097  0.01
2015 Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, et al. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial. The Lancet. Infectious Diseases. 15: 785-92. PMID 26062880 DOI: 10.1016/S1473-3099(15)00096-1  0.01
2015 Mora-Rillo M, Arsuaga M, Ramírez-Olivencia G, de la Calle F, Borobia AM, Sánchez-Seco P, Lago M, Figueira JC, Fernández-Puntero B, Viejo A, Negredo A, Nuñez C, Flores E, Carcas AJ, Jiménez-Yuste V, ... ... Arribas JR, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. The Lancet. Respiratory Medicine. PMID 26041403 DOI: 10.1016/S2213-2600(15)00180-0  0.01
2015 Berenguer J, Polo R, Aldeguer JL, Lozano F, Aguirrebengoa K, Arribas JR, Blanco JR, Boix V, Casado JL, Clotet B, Crespo M, Domingo P, Estrada V, García F, et al. Executive summary of the GESIDA/National AIDS Plan Consensus Document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2015). Enfermedades Infecciosas Y Microbiología ClíNica. 33: 544-56. PMID 26021186 DOI: 10.1016/j.eimc.2015.03.017  0.01
2015 Estébanez M, Bernardino JI, Serrano L, Pérez-Valero I, Zamora FX, Montes-Ramírez ML, González-García JJ, Arribas JR. Switching from tenofovir containing regimens to boosted protease inhibitor monotherapy: Impact on renal function. Enfermedades Infecciosas Y Microbiologia Clinica. PMID 25735716 DOI: 10.1016/j.eimc.2015.01.013  0.01
2015 Yazdanpanah Y, Arribas JR, Malvy D. Treatment of Ebola virus disease. Intensive Care Medicine. 41: 115-7. PMID 25385474 DOI: 10.1007/s00134-014-3529-8  0.01
2014 Górriz JL, Gutiérrez F, Trullas JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofan F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, et al. Consensus document on the management of renal disease in HIV-infected patients. Nefrología : PublicacióN Oficial De La Sociedad EspañOla Nefrologia. 34: 1-81. PMID 25467377 DOI: 10.3265/Nefrologia.pre2014.Jul.12674  0.01
2014 Górriz JL, Gutiérrez F, Trullas JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofan F, Domingo P, Estrada V, Fulladosa X, Galindo MJ, Gracia S, Iribarren JA, Knobel H, et al. Executive summary of the consensus document on the management of renal disease in HIV-infected patients. Nefrología : PublicacióN Oficial De La Sociedad EspañOla Nefrologia. 34: 768-88. PMID 25415577 DOI: 10.3265/Nefrologia.pre2014.Sep.12745  0.01
2014 Reeves I, Fisher M, Kegg S, Arribas J, Dau L, Garner W, Walker I, Nguyen T. Renal safety profile of STB in virologically suppressed subjects from two randomized phase 3b switch trials. Journal of the International Aids Society. 17: 19807. PMID 25397551  0.01
2014 Arribas J, Rizzardini G, Arasteh K, Zurawski C, Dietz C, Pontani D, Garner W, Nguyen T. Simplification to Stribild vs continuation of RTV-boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-PI subgroup analysis. Journal of the International Aids Society. 17: 19805. PMID 25397549  0.01
2014 Arribas J, Girard PM, Paton N, Winston A, Marcelin AG, Elbirt D, Hill A, Hadacek MB. Efficacy of PI monotherapy versus triple therapy for 1964 patients in 10 randomised trials. Journal of the International Aids Society. 17: 19788. PMID 25397532  0.01
2014 Gonzalez-Baeza A, Perez-Valero I, Carvajal-Molina F, Bayon C, Montes-Ramirez M, Bernardino JI, Arribas JR. Facial emotional processing deficits in long-term HIV-suppressed patients. Journal of the International Aids Society. 17: 19664. PMID 25397414  0.01
2014 Gatell JM, Arribas JR, Lázaro P, Blasco A. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults. Journal of the International Aids Society. 17: 19603. PMID 25394107  0.01
2014 Valero IP, Baeza AG, Hernandez-Tamames JA, Monge S, Arnalich F, Arribas JR. Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy. Journal of the International Aids Society. 17: 19578. PMID 25394085  0.01
2014 Cahn P, Villanueva JA, Arribas J, Gatell J, Lama J, Norton M, Patterson P, Madero JS, Sued O, Figueroa MI, Rolón MJ. Changes in lipid levels after 48 weeks of dual versus triple therapy observed in the GARDEL study. Journal of the International Aids Society. 17: 19554. PMID 25394061  0.01
2014 Antinori A, Arribas J, Fehr J, Girard PM, Horban A, Hill A, van Delft Y, Moecklinghoff C, Hill A. The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL. Journal of the International Aids Society. 17: 19525. PMID 25394034  0.01
2014 Solomon A, Tennakoon S, Leeansyah E, Arribas J, Hill A, Van Delft Y, Moecklinghoff C, Lewin SR. No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial. Plos One. 9: e109718. PMID 25368992 DOI: 10.1371/journal.pone.0109718  0.01
2014 Gorriz JL, Gutiérrez F, Trullàs JC, Arazo P, Arribas JR, Barril G, Cervero M, Cofán F, Domingo P, Estrada V, Fulladosa X, et al. [Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients]. Enfermedades Infecciosas Y Microbiología ClíNica. 32: 583-97. PMID 25303781 DOI: 10.1016/j.eimc.2014.09.002  0.01
2014 Estébanez M, Stella-Ascariz N, Mingorance J, Pérez-Valero I, González-Baeza A, Bayón C, Lakatos B, Borobia A, Arnalich F, Arribas JR. A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 419-23. PMID 25197825 DOI: 10.1097/QAI.0000000000000337  0.01
2014 Pérez-Valero I, González-Baeza A, Estébanez M, Monge S, Montes-Ramírez ML, Bayón C, Pulido F, Bernardino JI, Zamora FX, González-García JJ, Lagarde M, Hernando A, Arnalich F, Arribas JR. A prospective cohort study of neurocognitive function in aviremic HIV-infected patients treated with 1 or 3 antiretrovirals. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 1627-34. PMID 25114032 DOI: 10.1093/cid/ciu640  0.01
2014 Raffi F, Babiker AG, Richert L, Molina JM, George EC, Antinori A, Arribas JR, Grarup J, Hudson F, Schwimmer C, Saillard J, Wallet C, Jansson PO, Allavena C, Van Leeuwen R, et al. Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial. Lancet (London, England). 384: 1942-51. PMID 25103176 DOI: 10.1016/S0140-6736(14)61170-3  0.01
2014 Estébanez M, Stella-Ascariz N, Mingorance J, Pérez-Valero I, Bernardino JI, Zamora FX, Montes ML, González-García JJ, Arribas JR. Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study. Bmc Infectious Diseases. 14: 379. PMID 25015544 DOI: 10.1186/1471-2334-14-379  0.01
2014 Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, ... ... Arribas JR, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. The New England Journal of Medicine. 371: 234-47. PMID 25014688 DOI: 10.1056/NEJMoa1311274  0.01
2014 Berenguer J, Polo R, Lozano F, López Aldeguer J, Antela A, Arribas JR, Asensi V, Blanco JR, Clotet B, Domingo P, Galindo MJ, Gatell JM, González-García J, Iribarren JA, et al. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014). Enfermedades Infecciosas Y Microbiología ClíNica. 32: 447-58. PMID 24986715 DOI: 10.1016/j.eimc.2014.02.018  0.01
2014 Arribas JR, Pialoux G, Gathe J, Di Perri G, Reynes J, Tebas P, Nguyen T, Ebrahimi R, White K, Piontkowsky D. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial. The Lancet. Infectious Diseases. 14: 581-9. PMID 24908551 DOI: 10.1016/S1473-3099(14)70782-0  0.01
2014 Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, et al. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology. 83: 134-41. PMID 24907236 DOI: 10.1212/WNL.0000000000000564  0.01
2014 González-Baeza A, Carvajal F, Bayón C, Pérez-Valero I, Estébanez M, Bernardino JI, Monge S, Lagarde M, Hernando A, Arnalich F, Arribas JR. Pattern of neurocognitive function in patients receiving boosted protease inhibitor monotherapy: a detailed neuropsychological study. Journal of Neurovirology. 20: 362-70. PMID 24760361 DOI: 10.1007/s13365-014-0251-9  0.01
2014 Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung CC, Wilkin T, Vanveggel S, Stevens M, Deckx H. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 425-34. PMID 24729492 DOI: 10.1093/cid/ciu234  0.01
2014 Pozniak AL, Arribas JR. FLAMINGO: how much rosier can antiretroviral therapy get? Lancet (London, England). 383: 2191-3. PMID 24698484 DOI: 10.1016/S0140-6736(14)60447-5  0.01
2014 Montes ML, Schapiro J, Pérez-Valero I, García-Bujalance S, Arribas JR. Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance. Aids (London, England). 28: 932-4. PMID 24614067 DOI: 10.1097/QAD.0000000000000173  0.01
2014 Cohen C, Wohl D, Arribas JR, Henry K, Van Lunzen J, Bloch M, Towner W, Wilkins E, Ebrahimi R, Porter D, White K, Walker I, Chuck S, De-Oertel S, Fralich T. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. Aids (London, England). 28: 989-97. PMID 24508782 DOI: 10.1097/QAD.0000000000000169  0.01
2014 Montes Ramírez ML, Miró JM, Quereda C, Jou A, von Wichmann MÁ, Berenguer J, González-García JJ, Hernando A, Ortega E, Sanz J, Arribas JR. Incidence of hepatocellular carcinoma in HIV-infected patients with cirrhosis: a prospective study. Journal of Acquired Immune Deficiency Syndromes (1999). 65: 82-6. PMID 24419065 DOI: 10.1097/QAI.0b013e3182a685dc  0.01
2014 Hernández-Romero D, Vílchez JA, Lahoz Á, Romero-Aniorte AI, Orenes-Piñero E, Caballero L, Jara-Rubio R, Arribas JM, García-Alberola A, Valdés M, Lip GY, Marín F. High-sensitivity troponin T as a biomarker for the development of atrial fibrillation after cardiac surgery. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association For Cardio-Thoracic Surgery. 45: 733-8. PMID 24163361 DOI: 10.1093/ejcts/ezt488  0.01
2013 Pérez J, Arribas JM, Cárdenas E, Gutiérrez F, Taboada R, Cassinello N. Radiotherapeutic management of the chyloperitoneum following abdominal aortic aneurysm repair. Journal of Vascular Surgery. Venous and Lymphatic Disorders. 1: 409-411. PMID 26992764 DOI: 10.1016/j.jvsv.2013.02.002  0.01
2013 Arribas J, Pulido F, Hill A, Delft Yv, Moecklinghoff C. Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. International Journal of Std & Aids. 24: 679-81. PMID 24014249 DOI: 10.1177/0956462413486461  0.01
2013 Blasco AJ, Llibre JM, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, et al. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013]. Enfermedades Infecciosas Y Microbiología ClíNica. 31: 568-78. PMID 23969276 DOI: 10.1016/j.eimc.2013.06.002  0.01
2013 Pérez-Valero I, González-Baeza A, Estébanez M, Montes-Ramírez ML, Bayón C, Pulido F, Bernardino JI, Zamora FX, Monge S, Gaya F, Lagarde M, Rubio R, Hernando A, Arnalich F, Arribas JR. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. Plos One. 8: e69493. PMID 23936029 DOI: 10.1371/journal.pone.0069493  0.01
2013 Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H, Sedani S, Gartland M. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antiviral Therapy. 18: 905-13. PMID 23899468 DOI: 10.3851/IMP2667  0.01
2013 Arribas JR, Eron J. Advances in antiretroviral therapy. Current Opinion in Hiv and Aids. 8: 341-9. PMID 23666392 DOI: 10.1097/COH.0b013e328361fabd  0.01
2013 Pozniak AL, Arribas JR. A benchmark for management of drug resistant HIV. The Lancet. Infectious Diseases. 13: 561-2. PMID 23664332 DOI: 10.1016/S1473-3099(13)70113-0  0.01
2013 Geretti AM, Arribas JR, Lathouwers E, Foster GM, Yakoob R, Kinloch S, Hill A, van Delft Y, Moecklinghoff C. Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial. Hiv Clinical Trials. 14: 45-50. PMID 23372114 DOI: 10.1310/hct1401-45  0.01
2013 Arribas JR, Doroana M, Turner D, Vandekerckhove L, Streinu-Cercel A. Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting. Aids Research and Therapy. 10: 3. PMID 23347595 DOI: 10.1186/1742-6405-10-3  0.01
2013 Arribas JR. Initial antiretroviral therapy: the dilemmas ahead. Enfermedades Infecciosas Y Microbiología ClíNica. 31: 68-70. PMID 22939567 DOI: 10.1016/j.eimc.2012.07.011  0.01
2013 Estebanez M, Stella-Ascariz N, Ruiz-Carrascoso G, Zamora FX, García-Bujalance S, Bernardino JI, Pérez-Valero I, Martin-Quirós A, Mingorance J, Arribas JR. Is etravirine and two nucleosides an option for HIV with an isolated K103N mutation? Aids (London, England). 27: 141-4. PMID 22914581 DOI: 10.1097/QAD.0b013e328358fcc2  0.01
2012 Zúñiga RV, Arribas JL, Montes SP, Fernandez MN, Abad CG, Martin LG, González-Sagrado M. Application of Pediatric Appendicitis Score on the emergency department of a secondary level hospital. Pediatric Emergency Care. 28: 489-92. PMID 22653450 DOI: 10.1097/PEC.0b013e3182586d34  0.01
2012 García-Bujalance S, Francisco CN, Rubio JM, Arribas JR, Gutierrez A. Imported Plasmodium falciparum malaria in HIV-infected patients: a report of two cases. Malaria Journal. 11: 136. PMID 22540214 DOI: 10.1186/1475-2875-11-136  0.01
2012 Blasco AJ, Arribas JR, Boix V, Clotet B, Domingo P, González-García J, Knobel H, López JC, Llibre JM, Lozano F, Miró JM, Podzamczer D, Santamaría JM, Tuset M, Zamora L, et al. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012]. Enfermedades Infecciosas Y Microbiología ClíNica. 30: 283-93. PMID 22525829 DOI: 10.1016/j.eimc.2012.02.016  0.01
2012 Arribas J, Hill A, Xi N, van Delft Y, Moecklinghoff C. Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial. The Journal of Antimicrobial Chemotherapy. 67: 1804-6. PMID 22454490 DOI: 10.1093/jac/dks102  0.01
2012 Pulido F, Arribas J, Hill A, Moecklinghoff C. No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues. Aids Research and Human Retroviruses. 28: 1167-9. PMID 22380531 DOI: 10.1089/AID.2011.0256  0.01
2012 Estébanez M, Arribas JR. Protease inhibitor monotherapy: what is its role? Current Hiv/Aids Reports. 9: 179-85. PMID 22362299 DOI: 10.1007/s11904-012-0112-1  0.01
2012 Estébanez-Muñoz M, Soto-Abánades CI, Ríos-Blanco JJ, Arribas JR. Updating our understanding of pulmonary disease associated with HIV infection. Archivos De BronconeumologíA. 48: 126-32. PMID 22257776 DOI: 10.1016/j.arbres.2011.12.001  0.01
2012 García-González C, García-Bujalance S, Ruiz-Carrascoso G, Arribas JR, González-García J, Bernardino JI, Pascual-Pareja JF, Martínez-Prats L, Delgado R, Mingorance J. Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. Diagnostic Microbiology and Infectious Disease. 72: 90-6. PMID 22078905 DOI: 10.1016/j.diagmicrobio.2011.09.020  0.01
2012 van Lunzen J, Maggiolo F, Arribas JR, Rakhmanova A, Yeni P, Young B, Rockstroh JK, Almond S, Song I, Brothers C, Min S. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. The Lancet. Infectious Diseases. 12: 111-8. PMID 22018760 DOI: 10.1016/S1473-3099(11)70290-0  0.01
2011 Blasco AJ, Arribas JR, Clotet B, Domingo P, González-García J, López-Bernaldo JC, Llibre JM, Lozano F, Podzamczer D, Santamaría JM, Tuset M, Zamora L, Lázaro P, Gatell JM. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy]. Enfermedades Infecciosas Y Microbiología ClíNica. 29: 721-30. PMID 22014894 DOI: 10.1016/j.eimc.2011.08.003  0.01
2011 Eron JJ, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. The Lancet. Infectious Diseases. 11: 907-15. PMID 21933752 DOI: 10.1016/S1473-3099(11)70196-7  0.01
2011 McKinnon JE, Delgado R, Pulido F, Shao W, Arribas JR, Mellors JW. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antiviral Therapy. 16: 725-32. PMID 21817194 DOI: 10.3851/IMP1812  0.01
2011 Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, Vernazza P, Cahn P, Meynard JL, Arribas J, Bucher HC. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. Plos One. 6: e22003. PMID 21811554 DOI: 10.1371/journal.pone.0022003  0.01
2011 Llibre JM, Arribas JR, Domingo P, Gatell JM, Lozano F, Santos JR, Rivero A, Moreno S, Clotet B. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy. Aids (London, England). 25: 1683-90. PMID 21673556 DOI: 10.1097/QAD.0b013e3283499cd9  0.01
2011 Perez-Valero I, Bayon C, Cambron I, Gonzalez A, Arribas JR. Protease inhibitor monotherapy and the CNS: peace of mind? The Journal of Antimicrobial Chemotherapy. 66: 1954-62. PMID 21672918 DOI: 10.1093/jac/dkr229  0.01
2011 Bernardino JI, Mora M, Zamora FX, Arribas B, Montes ML, Pascual-Pareja F, Jose BS, Peña JM, Arribas JR. Hypertension and isolated office hypertension in HIV-infected patients determined by ambulatory blood pressure monitoring: prevalence and risk factors. Journal of Acquired Immune Deficiency Syndromes (1999). 58: 54-9. PMID 21654497 DOI: 10.1097/QAI.0b013e3182267406  0.01
2011 Clumeck N, Rieger A, Banhegyi D, Schmidt W, Hill A, Van Delft Y, Moecklinghoff C, Arribas J. 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. The Journal of Antimicrobial Chemotherapy. 66: 1878-85. PMID 21652619 DOI: 10.1093/jac/dkr199  0.01
2011 López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, Tural C, Hernando A, González-García J, Serrano L, Arribas JR. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. Aids (London, England). 25: 899-904. PMID 21330908 DOI: 10.1097/QAD.0b013e3283454174  0.01
2011 Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy. Antiviral Therapy. 16: 59-65. PMID 21311109 DOI: 10.3851/IMP1710  0.01
2011 Lejeune M, Miró JM, De Lazzari E, García F, Claramonte X, Martínez E, Ribera E, Arrizabalaga J, Arribas JR, Domingo P, Ferrer E, Plana M, Valls ME, Podzamczer D, Pumarola T, et al. Restoration of T cell responses to toxoplasma gondii after successful combined antiretroviral therapy in patients with AIDS with previous toxoplasmic encephalitis. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 52: 662-70. PMID 21292671 DOI: 10.1093/cid/ciq197  0.01
2011 Paton NI, Meynard JL, Pulido F, Arenas-Pinto A, Girard PM, Arribas J. Inappropriate claim of 'failure of ritonavir-boosted lopinavir monotherapy in HIV' in the Monotherapy Switzerland/Thailand (MOST) trial. Aids (London, England). 25: 393-4. PMID 21239897 DOI: 10.1097/QAD.0b013e328342fb7b  0.01
2011 Pérez-Valero I, Arribas JR. Protease inhibitor monotherapy. Current Opinion in Infectious Diseases. 24: 7-11. PMID 21150592 DOI: 10.1097/QCO.0b013e3283422cdf  0.01
2010 Llibre JM, Antela A, Arribas JR, Domingo P, Gatell JM, López-Aldeguer J, Lozano F, Miralles C, Moltó J, Moreno S, Ortega E, Riera M, Rivero A, Villalonga C, Clotet B. [Role of fixed-dose combinations of antiretrovirals in HIV-1 therapy]. Enfermedades Infecciosas Y Microbiología ClíNica. 28: 615-20. PMID 20888082 DOI: 10.1016/j.eimc.2010.08.004  0.01
2010 Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G, Sprenger HG, Lambert J, Sture G, Leather D, Hughes S, Zucchi P, Pearce H, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 51: 963-72. PMID 20828304 DOI: 10.1086/656417  0.01
2010 Perez-Valero I, Zamora FX, Pulido F, Arribas JR. Incorrect attribution of cerebrospinal fluid HIV-1 virological escape and lymphocytic meningitis to lopinavir/ritonavir monotherapy. Aids (London, England). 24: 2415-6. PMID 20827057 DOI: 10.1097/QAD.0b013e32833d56a5  0.01
2010 Winston A, Fätkenheuer G, Arribas J, Hill A, van Delft Y, Moecklinghoff C. Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study. Hiv Clinical Trials. 11: 163-9. PMID 20736152 DOI: 10.1310/hct1103-163  0.01
2010 Lifson AR, Neuhaus J, Arribas JR, van den Berg-Wolf M, Labriola AM, Read TR. Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. American Journal of Public Health. 100: 1896-903. PMID 20724677 DOI: 10.2105/AJPH.2009.188664  0.01
2010 Miró JM, Manzardo C, Pich J, Domingo P, Ferrer E, Arribas JR, Ribera E, Arrizabalaga J, Loncá M, Cruceta A, de Lazzari E, Fuster M, Podzamczer D, Plana M, Gatell JM, et al. Immune reconstitution in severely immunosuppressed antiretroviral-naive HIV type 1-infected patients using a nonnucleoside reverse transcriptase inhibitor-based or a boosted protease inhibitor-based antiretroviral regimen: three-year results (The Advanz Trial): a randomized, controlled trial. Aids Research and Human Retroviruses. 26: 747-57. PMID 20624069 DOI: 10.1089/aid.2009.0105  0.01
2010 Arribas JR, Rivero A, Leal M, Sánchez-de la Rosa R. [Human immunodeficiency virus (HIV) type 1 with R5 tropism among HIV-1 antiretroviral-experienced patients in Spain]. Enfermedades Infecciosas Y Microbiología ClíNica. 28: 559-60. PMID 20400209 DOI: 10.1016/j.eimc.2009.10.005  0.01
2010 Estébanez-Muñoz M, Montes ML, Ruiz-Seco P, Royo-Orejas A, González-García J, Arribas JR. [Demyelinating disease in human immunodeficiency virus-infected patients without severe immunodepression]. Enfermedades Infecciosas Y Microbiología ClíNica. 28: 608-11. PMID 20381930 DOI: 10.1016/j.eimc.2009.12.007  0.01
2010 Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F. The future of antiretroviral therapy: challenges and needs. The Journal of Antimicrobial Chemotherapy. 65: 827-35. PMID 20228080 DOI: 10.1093/jac/dkq061  0.01
2010 Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, Pulido F, Hill A, van Delft Y, Stark T, Moecklinghoff C. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. Aids (London, England). 24: 223-30. PMID 20010070 DOI: 10.1097/QAD.0b013e3283348944  0.01
2010 Rybniker J, Goede V, Mertens J, Ortmann M, Kulas W, Kochanek M, Benzing T, Arribas JR, Fätkenheuer G. Treatment of visceral leishmaniasis with intravenous pentamidine and oral fluconazole in an HIV-positive patient with chronic renal failure--a case report and brief review of the literature. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. 14: e522-5. PMID 19726213 DOI: 10.1016/j.ijid.2009.06.010  0.01
2010 Bernardino de la Serna JI, Zamora FX, Montes ML, García-Puig J, Arribas JR. [Hypertension, HIV infection, and highly active antiretroviral therapy]. Enfermedades Infecciosas Y Microbiología ClíNica. 28: 32-7. PMID 19409669 DOI: 10.1016/j.eimc.2008.07.005  0.01
2009 Arribas JR. Drugs in traditional drug classes (nucleoside reverse transcriptase inhibitor/nonnucleoside reverse transcriptase inhibitor/protease inhibitors) with activity against drug-resistant virus (tipranavir, darunavir, etravirine). Current Opinion in Hiv and Aids. 4: 507-12. PMID 20048718 DOI: 10.1097/COH.0b013e328331b911  0.01
2009 Pozniak A, Gupta RK, Pillay D, Arribas J, Hill A. Causes and consequences of incomplete HIV RNA suppression in clinical trials. Hiv Clinical Trials. 10: 289-98. PMID 19906623 DOI: 10.1310/hct1005-289  0.01
2009 Arribas JR, Mora M, Pascual-Pareja JF. Early versus deferred antiretroviral therapy for HIV. The New England Journal of Medicine. 361: 823; author reply 82. PMID 19701985  0.01
2009 Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, ... Arribas JR, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antiviral Therapy. 14: 195-201. PMID 19430094  0.01
2009 Pascual-Pareja JF, Caminoa A, Larrauri C, González-García J, Montes ML, Díez J, Grande M, Arribas JR. HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells/microl at the time of liver biopsy. Aids (London, England). 23: 971-5. PMID 19425223  0.01
2008 Arribas JR. [Role of the new molecules in antiretroviral therapy. Position of raltegravir]. Enfermedades Infecciosas Y Microbiología ClíNica. 26: 53-9. PMID 19572427  0.01
Hide low-probability matches.